COMING SOON!

This GCP Training: ICH GCP E6(R3) comprehensive course focuses on the latest revisions in Good Clinical Practice (GCP). The training presents in-depth knowledge about the requirements of GCP for clinical trials found in ICH E6(R3) related to the role and responsibilities of the investigator, sponsor, and other stakeholders. Content includes an overview of GCP and the GCP principles; responsibilities for stakeholders for maintaining GCP; essential records; informed consent and ethics committees; computerized systems and data governance, and good documentation practices including ALCOA+. The course contains practical knowledge to implement best practices and supports GCP and regulatory compliance across all phases of clinical research. The training included real-life case scenarios to apply what you have learned.

This course can be used alone or as part of the full curriculum; for more information refer to the additional information below.

Course Length: 3.5 hours

Includes:

• Unlimited access to the content for 45 days from your initial day of purchase.

• Certificate of completion

• Case Studies

• Post-Assessment

• Knowledge Checks

Learning Objectives

1. Apply critical thinking techniques for effective implementation of the global Good Clinical Practice Guideline, ICH E6(R3)

2. Discover how the changes in the guideline affect organizational processes and stakeholder roles and responsibilities

3. Identify practical applications of the guideline in your work processes

Audience

The course is designed for clinical research professionals, including sponsor and CRO personnel, investigators and site staff, or others involved in GCP activities.

ONBOARDING OR ANNUAL REVIEW CURRICULUM

This course can be used alone or as part of the full curriculum, including:

1. Good Documentation Practices and ALCOA-C - Available HERE

2. Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (ICH E2A) - Available HERE

3. Structure and Content of Clinical Study Reports (ICH E3) - Available HERE

4. Overview of 21 CFR 312 Investigational New Drug Application (IND) and 21 CFR 314 Application for FDA Approval to Market a New Drug (NDA) - Available HERE

5. Overview of 21 CFR Part 50 Human Subject Protection and 21 CFR Part 56 IRB/IEC - Available HERE

6. Overview of 21 CFR Part 11 Electronic Data / Signatures & 21 CFR Part 54 Financial Disclosure - HERE